AVROBIO Inc.

0.9819-0.0281-2.78%Vol 4.39M1Y Perf -89.50%
Jun 24th, 2022 16:00 DELAYED
BID0.9674 ASK1.05
Open1.00 Previous Close1.01
Pre-Market- After-Market1.14
 - -  0.16 16.10%
Target Price
4.33 
Analyst Rating
Moderate Buy 1.86
Potential %
340.98 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
2.36 
Earnings Rating
Sell
Market Cap42.91M 
Earnings Date
4th Aug 2022
Alpha-0.06 Standard Deviation0.23
Beta1.72 

Today's Price Range

0.95101.04

52W Range

0.740011.00

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
3.36%
1 Month
10.34%
3 Months
-35.40%
6 Months
-74.89%
1 Year
-89.50%
3 Years
-93.67%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AVRO0.9819-0.0281-2.78
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.58-0.68-17.24
Q04 2021-0.71-0.658.45
Q03 2021-0.74-0.75-1.35
Q02 2021-0.66-0.74-12.12
Q01 2021-0.77-0.6515.58
Q04 2020-0.87-0.7316.09
Q03 2020-0.81-1.01-24.69
Q02 2020-0.76-0.80-5.26
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.540.00-
9/2022 QR-0.495.77Positive
12/2022 FY-2.14-5.94Negative
12/2023 FY-1.82-1.11Negative
Next Report Date4th Aug 2022
Estimated EPS Next Report-0.54
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume4.39M
Shares Outstanding43.70K
Shares Float37.87M
Trades Count4.66K
Dollar Volume4.32M
Avg. Volume428.01K
Avg. Weekly Volume424.96K
Avg. Monthly Volume417.02K
Avg. Quarterly Volume442.04K

AVROBIO Inc. (NASDAQ: AVRO) stock closed at 0.9819 per share at the end of the most recent trading day (a -2.78% change compared to the prior day closing price) with a volume of 4.39M shares and market capitalization of 42.91M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 123 people. AVROBIO Inc. CEO is Geoff Mackay.

The one-year performance of AVROBIO Inc. stock is -89.5%, while year-to-date (YTD) performance is -74.5%. AVRO stock has a five-year performance of %. Its 52-week range is between 0.74 and 11, which gives AVRO stock a 52-week price range ratio of 2.36%

AVROBIO Inc. currently has a PE ratio of -0.30, a price-to-book (PB) ratio of 0.29, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -57.95%, a ROC of -60.11% and a ROE of -64.91%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from AVROBIO Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.54 for the next earnings report. AVROBIO Inc.’s next earnings report date is 04th Aug 2022.

The consensus rating of Wall Street analysts for AVROBIO Inc. is Moderate Buy (1.86), with a target price of $4.33, which is +340.98% compared to the current price. The earnings rating for AVROBIO Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AVROBIO Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AVROBIO Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 13.70, ATR14 : 0.09, CCI20 : 13.95, Chaikin Money Flow : -0.06, MACD : 0.00, Money Flow Index : 26.66, ROC : -7.37, RSI : 51.90, STOCH (14,3) : 48.83, STOCH RSI : 0.81, UO : 49.32, Williams %R : -51.17), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AVROBIO Inc. in the last 12-months were: Philip J. Vickers (Buy at a value of $40 080)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (57.14 %)
4 (50.00 %)
4 (50.00 %)
Moderate Buy
0 (0.00 %)
1 (12.50 %)
1 (12.50 %)
Hold
3 (42.86 %)
3 (37.50 %)
3 (37.50 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.86
Moderate Buy
1.88
Moderate Buy
1.88

AVROBIO Inc.

Avrobio Inc is a clinical-stage gene therapy company. It is engaged in the development of potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company manufactures products include AVR-RD-02, AVR-RD-03, and AVR-RD-04 which are used for various diseases such as Fabry, Gaucher, Pompe, and Cystinosis.

CEO: Geoff Mackay

Telephone: +1 617 914-8420

Address: One Kendall Square, Cambridge 02139, MA, US

Number of employees: 123

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

83%17%

Bearish Bullish

59%41%

Bearish Bullish

61%39%

News

Stocktwits